期刊文献+

树突状细胞在肿瘤中的作用

下载PDF
导出
摘要 恶性肿瘤是当今严重威胁人类生命健康的疾病。据统计,癌症已经成为我国城市居民的首位死因和农村居民的第二位死因。如何提高其疗效,改善患者的预后,是临床亟待解决的关键问题。一般而言,肿瘤的治疗分为两个阶段:第一阶段是减瘤,对荷瘤患者通过传统的治疗手段,如手术、放疗或化疗,最大限度地消除肿瘤细胞,降低机体的瘤负荷。
出处 《重庆医学》 CAS CSCD 北大核心 2012年第11期1080-1082,I0002,共4页 Chongqing medicine
基金 军队临床高新技术重点资助项目(2010gxjs070)
  • 相关文献

参考文献30

  • 1Edwards BK,Brown ML,Wingo PA. Annual report to the nation on the status of cancer,1975-2002,featuring population based trends in cancer treatment[J].Journal of the National Cancer Institute,2005,(19):1407-1427.
  • 2林垚,李承博,侯东泽.肿瘤生物治疗新进展[J].中国实用医药,2009,4(1):225-226. 被引量:10
  • 3徐榕,江虹虹,宋海峰.树突状细胞疫苗研究的新策略[J].中国肿瘤,2011,20(2):92-97. 被引量:6
  • 4Hajek R,Butch AW. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma[J].Medical Oncology,2000,(01):2-15.
  • 5Gong JL,Nikrui N,Chen DS. Fusion of human ovarian carcinoma cells with autologous or allogenic dendritic cells induce antitumor immunity[J].Immunology,2000,(03):1705-1711.
  • 6Piemonti L,Monti P,Zerbi A. Generation and functional characterization of dendritic cells from patients with pancrestic carcinoma withs pecial regard to clinical applicability[J].Cancer Immunology Immunotherapy,2000,(10):544-550.
  • 7Kantoff PW,Higano CS,Shore MD. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J].New England Journal of Medicine,2010,(05):413-422.
  • 8Damiano V,Caputo R,Garofal OS. TLR9 agonist acts by different mechanisms synergizingwith bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts[J].Proceedings of the National Academy of Sciences(USA),2007,(30):12468-12473.
  • 9Lake RA,Robins on BW. Immunotherapy and chemotherapy a practical partnership[J].Nature Reviews Cancer,2005,(05):397-405.
  • 10Adams M,Navabi H,Croston D. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3(TLR3) agonist and tumour-derived exos omes in advanced ovarian cancer[J].Vaccine,2005,(17/18):2374-2378.

二级参考文献98

  • 1顾健人,杨胜利.要用系统性疾病的观念重新认识癌症[J].中华医学杂志,2005,85(8):505-507. 被引量:13
  • 2Nouri-Shirazi J, et al. Dendritic M, Banchereau J, Fay cell based tumor vaecines[J], hnmunol l,ett, 2000, 74 (1): 5-10.
  • 3Harzstark, Air and Small, EJ. Sipuleucel-T for the treatment of prostate cancer[J]. Dings Today (Bare), 2008, 44 (4): 271-278.
  • 4Felvara A, Norm M, Sehr P, et al. Dendritic eell-based tumor vaccine for cervical cancer lh results of a clinical pilot study in 15 individual patients[J]. J Cancer Res Clin Oncol, 2003, 129(9): 521-530.
  • 5Banehereau J, Palucka AK. Dendritic eells as therapeutic vaccines against cancer [J]. Nat Rev lmmunol, 2005, 5(4): 296-306.
  • 6Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of seWtumor antigen-specific CD8^+ T cells in patients with melanoma[J]. J hnmunol, 2005, 175(9): 6169-6176.
  • 7Zitvogel L, Mayordomo Jl, Tjandrawan T, et al. Therapy of murine tu- mors with tmnor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell l-associated cytokines [J]. J Exp Med, 1996, 183(1): 87-97.
  • 8Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity [J]. Nat Med, 1995, 1 (12): 1297-1302.
  • 9Flamand V, Sornasse T, Thielemans K, et al. Murine dendritic eells pulsed in vitro with tmnor antigen induce tumor resistance in vivo[J]. Eur J hnnmnol, 1994, 24(3): 605-610.
  • 10Grabbe S, Bruvers S, Gallo RL, et al. Tumor antigen presentation by murine epidermal cells[J]. J Immunol, 1991, 146 (10): 3656-3661.

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部